把癌症拦截在早期 与我们的投资者携手共创未来 Mirxes Holding Co. Ltd. 2629.HK 作为东南亚首家在香港交易所上市的生物科技公司,我们致力于利用专有科技、综合“端到端”能力以及紧密的合作伙伴关系,加速在主要亚太市场及其他地区的增长。我们邀请您浏览此页面,查阅财务报告、公司公告和演示文稿。这些资料都突显了我们通过早筛挽救生命和驱动长期股东价值的使命。 公告与通函 其他重要信息 企业管治 查看更多 财务报告 查看更多 投资者演示文稿 查看更多 分析师报告 查看更多 Featured 投资者咨询 T. +65 6816 2931 E. info@mirxes.com A. 2 Tukang Innovation Grove, #09-02 JTC MedTech Hub Singapore 618305 联系我们 联系我们 A Future Without Late Diagnosis Harnessing RNA science to detect cancer early and save lives. 公告与通告 Our Technology & Solutions in the Cancer Care Continuum LUNGClear GASTROClear APEX Tissue COMPASS Tissue ID3EAL Suite Discovery Genomics Biobanking Fortitude 2.1 Fortitude Syndromic Panel ID3EAL(TM) PanoramiR MiRNA Knowledge Panel Cancer Screening GASTROClear and LUNGClear in the market, more in the pipeline. Cancer Treatment Selection APEX and COMPASS for targeted and comprehensive Next Generation Sequencing (NGS) respectively. Discovery Genomics Genomics and bioinformatics services to enhance our partners’ biological system researches. Cancer Treatment Selection APEX and COMPASS for targeted and comprehensive Next Generation Sequencing (NGS) respectively. Discovery Genomics Genomics and bioinformatics services to enhance our partners’ biological system researches. Featured